stoxline Quote Chart Rank Option Currency Glossary
  
Cumberland Pharmaceuticals Inc. (CPIX)
5.2  0.6 (13.04%)    02-12 19:48
Open: 4.64
High: 5.29
Volume: 264,274
  
Pre. Close: 4.6
Low: 4.5191
Market Cap: 73(M)
Technical analysis
2025-02-12 4:43:53 PM
Short term     
Mid term     
Targets 6-month :  7.51 1-year :  8.77
Resists First :  6.42 Second :  7.51
Pivot price 3.57
Supports First :  3.74 Second :  2.07
MAs MA(5) :  4.64 MA(20) :  3.32
MA(100) :  1.9 MA(250) :  1.71
MACD MACD :  0.6 Signal :  0.5
%K %D K(14,3) :  61.9 D(3) :  57.7
RSI RSI(14): 73.3
52-week High :  6.42 Low :  1.03
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CPIX ] has closed below upper band by 17.0%. Bollinger Bands are 520.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 19 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.29 - 5.31 5.31 - 5.33
Low: 4.47 - 4.49 4.49 - 4.51
Close: 5.16 - 5.2 5.2 - 5.23
Company Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Headline News

Wed, 12 Feb 2025
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Crosses Above 200-Day Moving Average - Here's Why - MarketBeat

Sat, 08 Feb 2025
Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated by Analysts at StockNews.com - MarketBeat

Tue, 04 Feb 2025
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease - Benzinga

Tue, 04 Feb 2025
Cumberland's DMD Heart Disease Drug Shows Breakthrough 5.4% LVEF Improvement in Phase 2 | CPIX Stock News - StockTitan

Tue, 04 Feb 2025
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease - PR Newswire

Wed, 15 Jan 2025
Improved Revenues Required Before Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Stock's 26% Jump Looks Justified - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 14 (M)
Shares Float 8 (M)
Held by Insiders 44 (%)
Held by Institutions 14.6 (%)
Shares Short 439 (K)
Shares Short P.Month 1,470 (K)
Stock Financials
EPS -0.76
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.76
Profit Margin -29.6 %
Operating Margin -18.7 %
Return on Assets (ttm) -5.7 %
Return on Equity (ttm) -36.1 %
Qtrly Rev. Growth -9.9 %
Gross Profit (p.s.) 2.18
Sales Per Share 2.62
EBITDA (p.s.) -0.2
Qtrly Earnings Growth 0 %
Operating Cash Flow -1 (M)
Levered Free Cash Flow 4 (M)
Stock Valuations
PE Ratio -6.85
PEG Ratio 0
Price to Book value 2.93
Price to Sales 1.98
Price to Cash Flow -49.33
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android